Bo Hejdeman

1.7k total citations
49 papers, 1.1k citations indexed

About

Bo Hejdeman is a scholar working on Virology, Infectious Diseases and Immunology. According to data from OpenAlex, Bo Hejdeman has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Virology, 24 papers in Infectious Diseases and 20 papers in Immunology. Recurrent topics in Bo Hejdeman's work include HIV Research and Treatment (42 papers), Immune Cell Function and Interaction (17 papers) and HIV/AIDS drug development and treatment (17 papers). Bo Hejdeman is often cited by papers focused on HIV Research and Treatment (42 papers), Immune Cell Function and Interaction (17 papers) and HIV/AIDS drug development and treatment (17 papers). Bo Hejdeman collaborates with scholars based in Sweden, Italy and United Kingdom. Bo Hejdeman's co-authors include Britta Wahrén, Eric Sandström, Francesca Chiodi, Anders Sönnerborg, Gunnel Biberfeld, Göran Bratt, Jorma Hinkula, Charlotta Nilsson, Michael R. Betts and Jakob Michaëlsson and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of Clinical Microbiology.

In The Last Decade

Bo Hejdeman

48 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bo Hejdeman Sweden 20 573 558 325 287 207 49 1.1k
Erika Schlaepfer Switzerland 19 701 1.2× 593 1.1× 236 0.7× 208 0.7× 179 0.9× 33 1.1k
Diane L. Bolton United States 20 755 1.3× 504 0.9× 365 1.1× 306 1.1× 223 1.1× 43 1.2k
Ai Kawana‐Tachikawa Japan 19 528 0.9× 539 1.0× 365 1.1× 179 0.6× 341 1.6× 63 1.1k
Kathie Grovit‐Ferbas United States 14 549 1.0× 894 1.6× 464 1.4× 306 1.1× 228 1.1× 15 1.2k
Afam A. Okoye United States 13 517 0.9× 517 0.9× 273 0.8× 274 1.0× 130 0.6× 21 1.0k
Madelene Lindqvist United States 14 857 1.5× 598 1.1× 193 0.6× 286 1.0× 240 1.2× 22 1.2k
Annie David France 17 682 1.2× 864 1.5× 482 1.5× 233 0.8× 246 1.2× 22 1.2k
Cristina Cellerai Switzerland 16 610 1.1× 479 0.9× 315 1.0× 346 1.2× 143 0.7× 21 1.1k
John F. Krowka United States 18 771 1.3× 775 1.4× 374 1.2× 263 0.9× 174 0.8× 30 1.3k
Tomas Doyle United Kingdom 11 525 0.9× 641 1.1× 374 1.2× 291 1.0× 244 1.2× 14 1.1k

Countries citing papers authored by Bo Hejdeman

Since Specialization
Citations

This map shows the geographic impact of Bo Hejdeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Hejdeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Hejdeman more than expected).

Fields of papers citing papers by Bo Hejdeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Hejdeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Hejdeman. The network helps show where Bo Hejdeman may publish in the future.

Co-authorship network of co-authors of Bo Hejdeman

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Hejdeman. A scholar is included among the top collaborators of Bo Hejdeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Hejdeman. Bo Hejdeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bekele, Yonas, Tadepally Lakshmikanth, Yang Chen, et al.. (2019). Mass cytometry identifies distinct CD4+ T cell clusters distinguishing HIV-1–infected patients according to antiretroviral therapy initiation. JCI Insight. 4(3). 14 indexed citations
2.
Carlander, Christina, Leo Flamholc, Bo Hejdeman, et al.. (2018). Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. International Journal of Antimicrobial Agents. 51(5). 733–738. 19 indexed citations
3.
Nilsson, Charlotta, Karina Godoy‐Ramirez, Bo Hejdeman, et al.. (2013). Broad and Potent Cellular and Humoral Immune Responses After a Second Late HIV-Modified Vaccinia Virus Ankara Vaccination in HIV-DNA-Primed and HIV-Modified Vaccinia Virus Ankara-Boosted Swedish Vaccinees. AIDS Research and Human Retroviruses. 30(3). 299–311. 23 indexed citations
4.
Gudmundsdotter, Lindvi, Bo Hejdeman, Lena Andersson, et al.. (2013). Short-term HIV-1 treatment interruption is associated with dysregulated TLR-stimuli responsiveness. Human Vaccines & Immunotherapeutics. 9(10). 2103–2110. 2 indexed citations
5.
Munseri, Patricia, Muhammad Bakari, Mohamed Janabi, et al.. (2013). Declining HIV-1 prevalence and incidence among Police Officers – a potential cohort for HIV vaccine trials, in Dar es Salaam, Tanzania. BMC Public Health. 13(1). 722–722. 3 indexed citations
6.
Cagigi, Alberto, Simone Pensieroso, Nicolas Ruffin, et al.. (2013). Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients. Vaccine. 31(18). 2231–2237. 15 indexed citations
7.
Johansson, S., Erik Rollman, Amy W. Chung, et al.. (2011). NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients. Viral Immunology. 24(5). 359–368. 53 indexed citations
8.
Vivar, Nancy, Nicolas Ruffin, Stefano Sammicheli, et al.. (2011). Survival and Proliferation of CD28- T Cells During HIV-1 Infection Relate to the Amplitude of Viral Replication. The Journal of Infectious Diseases. 203(11). 1658–1667. 22 indexed citations
9.
Bratt, Göran, et al.. (2009). Sexually Transmitted Infections (STI) in Men Who Have Sex with Men (MSM). City Research Online (City University London). 3(1). 118–127.
10.
Johansson, S., Bo Hejdeman, Jorma Hinkula, et al.. (2009). NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients. Clinical Immunology. 134(2). 158–168. 13 indexed citations
11.
Gudmundsdotter, Lindvi, Charlotta Nilsson, Andreas Bråve, et al.. (2009). Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 27(33). 4468–4474. 54 indexed citations
12.
Gudmundsdotter, Lindvi, Daniela Bernasconi, Bo Hejdeman, et al.. (2008). Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. Vaccine. 26(40). 5182–5187. 11 indexed citations
13.
Gudmundsdotter, Lindvi, Catherine Burton, Guglielmo Rosignoli, et al.. (2008). Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization. Vaccine. 26(40). 5107–5110. 4 indexed citations
14.
Kindberg, Elin, Bo Hejdeman, Göran Bratt, et al.. (2006). A nonsense mutation (428G→A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS. 20(5). 685–689. 55 indexed citations
15.
Devito, Claudia, Bo Hejdeman, Jan Albert, Kristina Broliden, & Jorma Hinkula. (2006). Short Communication: Antiretroviral Therapy Does Not Induce HIV Type 1-Specific Neutralizing Activity against Autologous HIV Type 1 Isolates. AIDS Research and Human Retroviruses. 22(9). 908–911. 4 indexed citations
16.
Gudmundsdotter, Lindvi, Anna Sjödin, Bo Hejdeman, et al.. (2006). Therapeutic immunization for HIV. Springer Seminars in Immunopathology. 28(3). 221–230. 14 indexed citations
17.
Bratt, Göran, et al.. (2004). The reverse transcriptase (RT) mutation V118I is associated with virologic failure on abacavir-based antiretroviral treatment (ART) in HIV-1 infection. Scandinavian Journal of Infectious Diseases. 36(1). 40–45. 2 indexed citations
18.
Hejdeman, Bo, Sandra A. Calarota, Rodiça Lenkei, et al.. (2004). DNA Immunization with HIV Early Genes in HIV Type 1-Infected Patients on Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses. 20(8). 860–870. 23 indexed citations
19.
Hejdeman, Bo, et al.. (2001). Clinical and Immunological Benefits from Highly Active Antiretroviral Therapy in Spite of Limited Viral Load Reduction in HIV Type 1 Infection. AIDS Research and Human Retroviruses. 17(4). 277–286. 24 indexed citations
20.
Milito, Angelo De, Bo Hejdeman, Jan Albert, et al.. (2000). High Plasma Levels of Soluble Fas in HIV Type 1-Infected Subjects Are Not Normalized during Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses. 16(14). 1379–1384. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erika Schlaepfer Breakdown of academic impact, for papers by Diane L. Bolton Breakdown of academic impact, for papers by Ai Kawana‐Tachikawa Breakdown of academic impact, for papers by Kathie Grovit‐Ferbas Breakdown of academic impact, for papers by Afam A. Okoye Breakdown of academic impact, for papers by Madelene Lindqvist Breakdown of academic impact, for papers by Annie David Breakdown of academic impact, for papers by Cristina Cellerai Breakdown of academic impact, for papers by John F. Krowka Breakdown of academic impact, for papers by Tomas Doyle
Rankless by CCL
2026